ACTIVATION OF PROTHROMBIN IN WHOLE HUMAN BLOOD

这项研究最初是为了评估两者之间的关系 组织因子中的蛋白水解酶与血小板活化 诱导最小变化的全血凝结。这些技术是 目前正被用于两项不同但相关的研究。在一项研究中， 有出血或凝血异常的患者，包括各种 蛋白质缺乏症的研究。在另一项研究中，不同的血小板 抑制剂被添加到正常人的血液中，而 然后在存在和不存在这种情况下检查混凝过程 抑制剂。此外，阿斯匹林将在正常情况下使用 志愿者检测阿司匹林对凝血功能的影响 路径。 受试者被检测纤维蛋白原、凝血酶原时间并被激活 部分凝血活酶时间、血象和化学13谱图是 获得。对阿司匹林疗效研究的受试者进行测试 在服用阿司匹林之前和在服用阿司匹林650毫克/天后 几天。在对血小板抑制物的研究中，该抑制物存在于 加入血液的一系列管子，在对照组中不存在 系列片。

This study was initially conducted to evaluate the relationship between protease enzymology and platelet activation during the tissue factor induced clotting of minimally altered whole blood. These techniques are now being utilized in two different but related studies. In one study, patients with bleeding or clotting abnormalities, including various protein deficiencies, are studied. In the other study, various platelet inhibitors are added to the blood of normal individuals, and the coagulation process is then examined in the presence and absence of such inhibitors . In addition asprin will be administered to normal volunteers to examine the influence of aspirin in the blood clotting pathway. Subjects are tested for fibrinogen, prothrombin time and activated partial thromboplastin time and hemagrams and chem 13 profiles are obtained. Subjects in the study of the effects of aspirin are tested before aspirin is given and after receiving 650 mg/day aspirin for 3 days. In the study of platelet inhibitors, the inhibitor is present in one series of tubes to which blood is added and is absent in a control series.